Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Philippe Ronga"'
Autor:
Chiara Cremolini, Clara Montagut, Philippe Ronga, Filippo Venturini, Kensei Yamaguchi, Sebastian Stintzing, Alberto Sobrero
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
In patients with RAS wild-type metastatic colorectal cancer (mCRC), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody plus chemotherapy is a standard option for treatment in the first-line setting. Patients who progress while on tre
Externí odkaz:
https://doaj.org/article/1777e610457b4d03857d820d434f40e8
Autor:
Jesús García-Foncillas, Yu Sunakawa, Dan Aderka, Zev Wainberg, Philippe Ronga, Pauline Witzler, Sebastian Stintzing
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic
Externí odkaz:
https://doaj.org/article/a2f8d9a7ef634a0cab0fafba51101cf6
Publikováno v:
Journal of Comparative Effectiveness Research. 10:353-364
Aim: To compare healthcare resource utilization (HRU) and healthcare costs (HC) for every-2-week (Q2W) versus weekly (Q1W) cetuximab in metastatic colorectal cancer (mCRC). Patients & methods: Patients with mCRC receiving cetuximab plus chemotherapy
Autor:
Philippe Ronga, Bart Heeg, Volker Heinemann, Sebastian Stintzing, Ilse van Oostrum, Chris P Pescott
Publikováno v:
Journal of Medical Economics. 23:448-455
Aims: This analysis evaluates the cost-effectiveness of first-line treatment with FOLFIRI + cetuximab vs FOLFIRI + bevacizumab for patients with RAS wild-type (wt) metastatic colorectal cancer (mCR...
Autor:
Shaista Salim, Michael Batech, Francois-Xavier Lamy, Chris P Pescott, Emmanuelle Boutmy, Philippe Ronga
Publikováno v:
Journal of comparative effectiveness research. 9(16)
Aim: To test the noninferiority of cetuximab administered every 2 weeks (Q2W) versus once weekly (Q1W) in treating metastatic colorectal cancer (mCRC) with regard to overall survival (OS). Patients: Patients receiving cetuximab plus chemotherapy for
Autor:
Sebastian, Stintzing, Ilse, van Oostrum, Chris P, Pescott, Philippe, Ronga, Bart, Heeg, Volker, Heinemann
Publikováno v:
Journal of medical economics. 23(5)
Autor:
Timmy Chan, Susan Dooley, Brian Draganic, Andrea Tannapfel, Klaus-Peter Janssen, Amanda Lucas, Heiner Wolters, Waldemar Uhl, Cliff Meldrum, Peter Pockney, Wolff Schmiegel, Daniel L. Edelstein, Richard Viebahn, Steve Smith, Stephan A. Hahn, Frederick S. Jones, Philippe Ronga, Michael Pohl, Chelsee A. Hewitt, Deepak Vangala, Danilo Acosta, Helmut Friess, Barbara Dockhorn-Dworniczak, Anke Reinacher-Schick, Rodney J. Scott, S. Hegewisch-Becker, Alexander Baraniskin, Su Ping-Chang, Josef Stern, Julia Slotta-Huspenina, Ulrich Nitsche, Hazel Philimore, Wendy Lewis, Stephen B. Fox, Elva Shi, Christian Teschendorf, Kateh Namdarian
Publikováno v:
Molecular Oncology
An accurate blood-based RAS mutation assay to determine eligibility of metastatic colorectal cancer (mCRC) patients for anti-EGFR therapy would benefit clinical practice by better informing decisions to administer treatment independent of tissue avai
Autor:
Philippe Ronga, Yu Sunakawa, Jesus Garcia-Foncillas, Zev A. Wainberg, Pauline Witzler, Dan Aderka, Sebastian Stintzing
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 9 (2019)
Biblos-e Archivo. Repositorio Institucional de la UAM
Consejo Superior de Investigaciones Científicas (CSIC)
Frontiers in Oncology, Vol 9 (2019)
Biblos-e Archivo. Repositorio Institucional de la UAM
Consejo Superior de Investigaciones Científicas (CSIC)
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c3ed371e342f7cbbfd3189be2157d71
https://hdl.handle.net/10486/690690
https://hdl.handle.net/10486/690690
Publikováno v:
Journal of Clinical Oncology. 38:23-23
23 Background: Cetuximab (CET) administered weekly (q1w) at 250 mg/m², after an initial dose of 400 mg/m², is approved in combination with chemotherapy (CT) for the treatment of (K) RAS wild-type metastatic colorectal cancer (mCRC). The use of CET
Autor:
Richard M. Goldberg, Zev A. Wainberg, Julien Taieb, Salvatore Siena, Clara Montagut, Daniele Santini, Sebastian Stintzing, Philippe Ronga, François Audhuy
Publikováno v:
ESMO open, vol 3, iss 4
ESMO Open
ESMO Open
The anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with chemotherapy is a standard of care in the first-line treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) and has demonstrated efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23def998f990700530f175595874a5c1
http://hdl.handle.net/10230/37121
http://hdl.handle.net/10230/37121